- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03851835
Multi-DOSE Oral Ondansetron for Pediatric Acute GastroEnteritis (DOSE-AGE)
Multi-dose Oral Ondansetron For Pediatric Gastroenteritis: A Pragmatic Randomized Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The annual burden of acute gastroenteritis in the United States includes 17 million related episodes and 473,832 hospitalizations. Although oral-rehydration therapy is recommended for children with mild-to-moderate dehydration, it has historically been underused with emergency department (ED) clinicians being more likely to choose intravenous over oral rehydration especially when vomiting is a major symptom. In fact, nearly 95% of children undergoing oral rehydration in Canadian EDs present with recent vomiting. To address this issue, the investigators conducted both a landmark clinical trial and a recent meta-analysis that have demonstrated that the ED use of ondansetron, an anti-emetic, leads to reductions in intravenous rehydration and hospitalization and is cost-effective. However, the available data revealed some associations with increased diarrhea and no evidence of benefits associated with ongoing ondansetron use following ED discharge. Despite the lack of available data, the provision of multiple doses of ondansetron for home use has become routine in many EDs across North America. The literature has differing opinions on the topic of ongoing ondansetron use after ED discharge and given the limited evidence supporting its use, the potential side effects and additional cost, there is an urgent need to definitively evaluate the effect of multiple doses of ondansetron in children, focusing on family-centred, post-index visit outcomes.
A phase III, double-blind, parallel-design, randomized, placebo controlled trial to compare multi-dose oral Ondansetron with placebo as treatment for vomiting secondary to acute gastroenteritis (AGE), after Emergency Department discharge will be conducted. Children and youth, age 6 months to 17.99 years will be enrolled at six (6) Canadian Emergency Departments. The total number of participants recruited will be 1030. Participants will be enrolled at six (6) pediatric emergency departments across Canada.
Children who are provided a minimum of one dose of ondansetron as part of their routine clinical care AND meet other eligibility criteria will be randomized to receive an at-home kit with six (6) doses of Ondansetron Hydrochloride Dihydrate Oral Solution (4mg/5mL solution; dosed at 0.15mg/kg to a maximum single dose of 8mg) or equivalent volume in a Placebo Oral Solution to be administered no sooner than 8 hours after the initial clinical dose was provided by the ED physician. Over the subsequent 48 hours, the study intervention will be administered at a rate of 1 dose every 8 hours (q8h) to a maximum of 3 doses a day (in a 24 hour period (TID)) at the caregiver's discretion. Two (2) additional doses will be provided to the caregiver in case the child vomits a dose.
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Sarah Williamson-Urquhart
- Phone Number: 403-955-2482
- Email: sarah.urquhart@ahs.ca
Study Contact Backup
- Name: Stephen Freedman, MD
- Phone Number: 403-955-7740
- Email: stephen.freedman@ahs.ca
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada, T3B 6A8
- Recruiting
- Alberta Children's Hospital
-
Contact:
- Sarah Williamson-Urquhart
- Phone Number: 403-955-2482
- Email: sarah.urquhart@ahs.ca
-
Principal Investigator:
- Stephen Freedman, MD
-
Sub-Investigator:
- Graham Thompson, MD
-
Sub-Investigator:
- Antonia Stang, MD
-
Edmonton, Alberta, Canada, T6G 2C8
- Recruiting
- Stollery Children's Hospital
-
Principal Investigator:
- Andrew Dixon, MD
-
Contact:
- Patricia Candelaria
- Phone Number: 780-248-5440
- Email: stacruz@ualberta.ca
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3A 1S1
- Recruiting
- Children's Hospital of Winnipeg
-
Contact:
- Jeannine Schellenberg
- Phone Number: 204-789-3206
- Email: JSchellenberg@chrim.ca
-
Principal Investigator:
- Darcy Beer, MD
-
Sub-Investigator:
- Scott Sawyer, MD
-
-
Ontario
-
London, Ontario, Canada, N6A 5W9
- Recruiting
- Children's Hospital London Health Sciences Centre
-
Principal Investigator:
- Gary Joubert, MD
-
Contact:
- Patrick Siedlecki, PhD
- Phone Number: 56174 519-685-8500
- Email: Leslie.Boisvert@lhsc.on.ca
-
Ottawa, Ontario, Canada, K1H 8L1
- Active, not recruiting
- Children's Hospital of Eastern Ontario (CHEO)
-
-
Quebec
-
Montreal, Quebec, Canada, HT3 1C5
- Active, not recruiting
- Centre Hospitalier Universitaire Sainte Justine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosis of acute intestinal infectious process (as defined by the protocol) confirmed. by the treating MD.
- Age 6 months to 17.99 years.
- Presence of ≥ 3 episodes of vomiting in the preceding 24 hour period.
- Duration of vomiting and/or diarrheal symptoms < 72 hours.
- A minimum of 1 episode of vomiting within 6 hours of the screening process performed by the research team.
- A minimum of 1 dose of ondansetron (oral or intravenous) provided during the current emergency department visit.
Exclusion Criteria:
- Bilious or bloody vomit during current illness.
- Known hypersensitivity to ondansetron or any serotonin receptor antagonist (e.g. palonosetron, dolasetron, granisetron).
- Known allergic reaction to components of ondansetron (citric acid, sodium benzoate, sodium citrate dihydrate, and strawberry flavor, sorbitol) or the placebo medication (methylparaben, glycerin, citric acid, potassium sorbate, sorbitol, strawberry flavor).
- History or family history (first degree relative) of prolonged QT syndrome.
- Presence of complex congenital heart disease.
- History or family history (first degree relative) of cardiac arrhythmia.
- Concomitant use (within the past 48 hours) of any of the following: QTc prolonging medications, medications known to cause torsades de pointes, medications that cause electrolyte abnormalities, serotonergic or neuroleptic medications, or any 5-HT3 receptor antagonist excluding ondansetron.
- History or family history of G6PD deficiency
- Unable to complete follow-up.
- Previously enrolled in this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ondansetron Oral Solution
Ondansetron Oral Solution (4mg/5mL solution) - Dose = 0.15mg/kg.
One dose every 8 hours (q8h).
Six doses over 48 hours.
|
Six doses of oral ondansetron (0.15mg/kg) to be administered q8h (every 8 hours) to a maximum of 3 times in a 24 hour period, are provided to the participant/caregiver for use after emergency department disposition (i.e. home use).
Other Names:
|
Placebo Comparator: Placebo Oral Solution
Compounded Placebo Oral Solution to match experimental arm
|
Six doses of oral placebo (0.15mg/kg) to be administered q8h (every 8 hours) to a maximum of 3 times in a 24 hour period, are provided to the participant/caregiver for use after emergency department disposition (i.e. home use).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Development of moderate to severe disease as defined by the Modified Vesikari Scale (MVS) Score of ≥ 9 following ED evaluation - change in the MVS score between Hour 0 and Hour 168 of the study.
Time Frame: Measured 24, 48, and 168 hours after baseline visit
|
The Modified Vesikari Scale Score (MVS) is a composite measure which includes several variables representing the severity of disease - points are summed to provide an overall score:
|
Measured 24, 48, and 168 hours after baseline visit
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Vomiting Duration
Time Frame: Measured 24, 48, and 168 hours after baseline visit
|
Number of hours of vomiting following ED disposition.
|
Measured 24, 48, and 168 hours after baseline visit
|
Vomiting Frequency
Time Frame: Measured 24, 48, and 168 hours after baseline visit
|
Number of episodes of vomiting following ED disposition.
|
Measured 24, 48, and 168 hours after baseline visit
|
Vomiting Proportion
Time Frame: Measured 24, 48, and 168 hours after baseline visit
|
The proportion who experience vomiting following ED disposition.
|
Measured 24, 48, and 168 hours after baseline visit
|
Proportion of participants who require an unscheduled health care visit
Time Frame: Measured 24, 48, and 168 hours after baseline visit
|
Unscheduled health care provider visits following Emergency Department disposition.
Is there a difference in the proportion who require an unscheduled health care provider visit following ED disposition.
|
Measured 24, 48, and 168 hours after baseline visit
|
Proportion of participants who require Intravenous (IV) Rehydration
Time Frame: Measured 24, 48, and 168 hours after baseline visit
|
Is there a difference in the proportion who require intravenous rehydration following ED disposition.
|
Measured 24, 48, and 168 hours after baseline visit
|
Satisfaction with care: 5 point Likert Scale
Time Frame: 168 hours after baseline
|
Caregivers will be asked about their level of satisfaction with the therapy provided measured on the following 5 point Likert scale (choose one option):
|
168 hours after baseline
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety Profile of Multiple Doses of Oral Ondansetron
Time Frame: Measured 24, 48, and 168 hours after baseline visit
|
To determine if the discharge of children with AGE associated vomiting who are administered ondansetron in the ED with additional doses to be taken at home is associated with adverse events (e.g.
diarrhea, revisits) as compared with placebo.
|
Measured 24, 48, and 168 hours after baseline visit
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Stephen Freedman, MD, University of Calgary
Publications and helpful links
General Publications
- Heath A, Rios JD, Williamson-Urquhart S, Pechlivanoglou P, Offringa M, McCabe C, Hopkin G, Plint AC, Dixon A, Beer D, Gouin S, Joubert G, Klassen TP, Freedman SB; PERC-KIDSCAN DOSE-AGE Study Group. A pragmatic randomized controlled trial of multi-dose oral ondansetron for pediatric gastroenteritis (the DOSE-AGE study): statistical analysis plan. Trials. 2020 Aug 24;21(1):735. doi: 10.1186/s13063-020-04651-1.
- Freedman SB, Williamson-Urquhart S, Heath A, Pechlivanoglou P, Hopkin G, Gouin S, Plint AC, Dixon A, Beer D, Joubert G, McCabe C, Finkelstein Y, Klassen TP; KidsCAN-Pediatric Emergency Research Canada (PERC) Innovative Pediatric Clinical Trials DOSE-AGE Study Group. Multi-dose Oral Ondansetron for Pediatric Gastroenteritis: study Protocol for the multi-DOSE oral ondansetron for pediatric Acute GastroEnteritis (DOSE-AGE) pragmatic randomized controlled trial. Trials. 2020 May 27;21(1):435. doi: 10.1186/s13063-020-04347-6.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Signs and Symptoms, Digestive
- Gastrointestinal Diseases
- Vomiting
- Diarrhea
- Gastroenteritis
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Antiemetics
- Gastrointestinal Agents
- Dermatologic Agents
- Serotonin Agents
- Serotonin Antagonists
- Serotonin 5-HT3 Receptor Antagonists
- Antipruritics
- Ondansetron
Other Study ID Numbers
- OND18-2045
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vomiting
-
Instituto Materno Infantil Prof. Fernando FigueiraUniversidade Federal de PernambucoCompleted
-
MonoSol RxCompletedNausea With Vomiting Chemotherapy-Induced | Nausea and Vomiting, PostoperativeIndia
-
GlaxoSmithKlineCompletedPostoperative Nausea and Vomiting | Nausea and Vomiting, PostoperativeUnited States, Spain, Philippines, Israel, Hong Kong, Thailand, United Kingdom, Hungary, Slovenia, Norway, Denmark
-
Hoffmann-La RocheCompletedPost-Operative Nausea and VomitingUnited States
-
Cairo UniversityUnknownPost Operative Nausea and VomitingEgypt
-
Yonsei UniversityCompletedPost Operative Nausea and VomitingKorea, Republic of
-
Oregon Health and Science UniversityCompletedPostoperative Vomiting and NauseaUnited States
-
AccentureCompletedPost-Operative Nausea and Vomiting (PONV)Australia
-
Methodist Health SystemRecruitingNausea, Postoperative | Vomiting, PostoperativeUnited States
-
GlaxoSmithKlineCompletedPostoperative Nausea and Vomiting | Nausea and Vomiting, PostoperativeUnited States, Hungary, Canada, Spain, Belgium, Germany
Clinical Trials on Ondansetron Oral Solution
-
Halozyme TherapeuticsCompleted
-
Foresee Pharmaceuticals Co., Ltd.CompletedHealthy VolunteersAustralia
-
Crinetics Pharmaceuticals Inc.CompletedHealthy VolunteersAustralia
-
AlzProtect SASActive, not recruitingProgressive Supranuclear PalsyFrance
-
Crinetics Pharmaceuticals Inc.CompletedHealthy VolunteersUnited States
-
Emergent BioSolutionsNational Institute of Allergy and Infectious Diseases (NIAID)TerminatedViral InfectionUnited States
-
IRCCS Burlo GarofoloCompleted
-
Galapagos NVCompletedHealthy | PsoriasisBelgium, Moldova, Republic of, Ukraine
-
Boehringer IngelheimCompletedHIV InfectionsUnited States, Argentina, Brazil, Canada, France, Germany, Italy, Mexico, Puerto Rico, Spain